Antibacterial and antivirulence activities of abafungin against Clostridioides difficile: in vitro and in vivo studies
5 affiliations
- 1Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA
- 2Department of Bacteriology, Mycology, and Immunology, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Menofia, Egypt
- 3Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig, Al-Sharqia, Egypt
- 4Department of Plant Pathology, Faculty of Agriculture, Assiut University, Assiut, Egypt
- 5Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA
Abstract
Clostridioides difficile infection (CDI) remains a major cause of healthcare-associated diarrhea worldwide, and is classified as an urgent public health threat by the Centers for Disease Control and Prevention. Current frontline therapies, including vancomycin and fidaxomicin, are associated with disruption of the intestinal microbiota, recurrence, and emerging reduced susceptibility, underscoring the need for additional therapeutic strategies. Using a drug-repurposing approach, we identified the antifungal agent abafungin as a potent inhibitor of C. difficile. Abafungin is an arylguanidine antifungal with reported sporicidal activity against fungal pathogens, a property of particular relevance to CDI, given the central role of spores in disease persistence and recurrence. Herein, abafungin exhibited potent in vitro activity against a diverse panel of clinical C. difficile isolates, inhibiting 50% (MIC5₀) and 90% (MIC₉₀) of the tested strains at the concentrations of 0.25 μg/mL and 0.5 μg/mL, respectively, while demonstrating minimal activity against representative gut commensal bacteria. At sub-inhibitory concentrations, abafungin significantly reduced toxin production (31.8%), decreased spore formation (~4-log₁₀ reduction), and inhibited spore germination. Abafungin showed favorable gastrointestinal stability and demonstrated synergistic activity with vancomycin and metronidazole. Transcriptomic analysis revealed that abafungin disrupts metal ion transport and intracellular metal homeostasis in C. difficile, a mechanism supported by the antagonistic effect of Mg²+ supplementation on its antibacterial activity. These observations suggest a potential association between abafungin activity and metal-responsive cellular pathways. In a murine model of recurrent CDI, a combination therapy of abafungin and vancomycin significantly improved survival (83.3%) compared with vancomycin monotherapy (16.6%). Collectively, these findings establish abafungin as a potential anti-C. difficile inhibitor that suppresses C. difficile growth and virulence-associated processes and enhances the therapeutic efficacy of vancomycin in vivo. Also, these observations provide a basis for further studies exploring abafungin as a useful lead scaffold for anti-C. difficile drug discovery.
Related
- Epidemiology, risk factors and outcomes of Clostridioides difficile infection in a UK district general hospital: a retrospective cohort study
- Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains
- Effects of Antibiotic Use Reduction on Clostridioides difficile Colonization in Nursing Homes
- Case Report: Immune-related colitis complicated by Clostridioides difficile-associated colitis
BibTeX
@article{abouelkhair2026antibacterial,
title = {{Antibacterial and antivirulence activities of abafungin against Clostridioides difficile: in vitro and in vivo studies}},
author = {Ahmed A. Abouelkhair and Nader S. Abutaleb and Sahar Abdelrazek and Mohamed N. Seleem},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
month = aug,
doi = {10.1128/aac.00598-26},
url = {https://doi.org/10.1128/aac.00598-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antibacterial and antivirulence activities of abafungin against Clostridioides difficile: in vitro and in vivo studies
AU - Ahmed A. Abouelkhair
AU - Nader S. Abutaleb
AU - Sahar Abdelrazek
AU - Mohamed N. Seleem
PY - 2026
DA - 2026/08/13
JO - Antimicrobial Agents and Chemotherapy
DO - 10.1128/aac.00598-26
UR - https://doi.org/10.1128/aac.00598-26
AB - Clostridioides difficile infection (CDI) remains a major cause of healthcare-associated diarrhea worldwide, and is classified as an urgent public health threat by the Centers for Disease Control and Prevention. Current frontline therapies, including vancomycin and fidaxomicin, are associated with disruption of the intestinal microbiota, recurrence, and emerging reduced susceptibility, underscoring the need for additional therapeutic strategies. Using a drug-repurposing approach, we identified the antifungal agent abafungin as a potent inhibitor of C. difficile. Abafungin is an arylguanidine antifungal with reported sporicidal activity against fungal pathogens, a property of particular relevance to CDI, given the central role of spores in disease persistence and recurrence. Herein, abafungin exhibited potent in vitro activity against a diverse panel of clinical C. difficile isolates, inhibiting 50% (MIC5₀) and 90% (MIC₉₀) of the tested strains at the concentrations of 0.25 μg/mL and 0.5 μg/mL, respectively, while demonstrating minimal activity against representative gut commensal bacteria. At sub-inhibitory concentrations, abafungin significantly reduced toxin production (31.8%), decreased spore formation (~4-log₁₀ reduction), and inhibited spore germination. Abafungin showed favorable gastrointestinal stability and demonstrated synergistic activity with vancomycin and metronidazole. Transcriptomic analysis revealed that abafungin disrupts metal ion transport and intracellular metal homeostasis in C. difficile, a mechanism supported by the antagonistic effect of Mg²+ supplementation on its antibacterial activity. These observations suggest a potential association between abafungin activity and metal-responsive cellular pathways. In a murine model of recurrent CDI, a combination therapy of abafungin and vancomycin significantly improved survival (83.3%) compared with vancomycin monotherapy (16.6%). Collectively, these findings establish abafungin as a potential anti-C. difficile inhibitor that suppresses C. difficile growth and virulence-associated processes and enhances the therapeutic efficacy of vancomycin in vivo. Also, these observations provide a basis for further studies exploring abafungin as a useful lead scaffold for anti-C. difficile drug discovery.
SN - 0066-4804
SN - 1098-6596
ER -